Development of tridentate iron chelators: from desferrithiocin to ICL670. - Wikidata - wikimedia - TriplyDB

Development of tridentate iron chelators: from desferrithiocin to ICL670.

Development of tridentate iron chelators: from desferrithiocin to ICL670.

http://www.wikidata.org/entity/Q35100327

about

Pharmacology of iron transport Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes Targeting iron metabolism in drug discovery and delivery Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.Hypersensitivity reaction with deferasirox.A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions.4-[3,5-Bis(2-hy-droxy-phen-yl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethyl-formamide monosolvate.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.Targeting iron assimilation to develop new antibacterials.Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.Deferasirox: appraisal of safety and efficacy in long-term therapy.Korean guideline for iron chelation therapy in transfusion-induced iron overload.Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.Desferrithiocin analogues and nephrotoxicity.Malaria and iron: history and review.Deferasirox: an update.Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.The impact of hematopoietic stem cell transplantation on the management of thalassemia.Design of clinically useful macromolecular iron chelators.Deferasirox: pharmacokinetics and clinical experience.Different approaches to the study of chelating agents for iron and aluminium overload pathologies.Iron chelation in the treatment of cancer: a new role for deferasirox?Clinical pharmacology of deferasirox.Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.Role of pharmacogenetics on deferasirox AUC and efficacy.Deferoxamine synergistically enhances iron-mediated AP-1 activation: a showcase of the interplay between extracellular-signal-regulated kinase and tyrosine phosphatase.New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Recent advances in β-thalassemias Update on the use of deferasirox in the management of iron overload.Iron chelation therapy in thalassemia syndromes Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.Four-component synthesis of fully substituted 1,2,4-triazoles.Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.

P2860

Q27009387-6880E5B8-D8DA-4710-A7A3-8A189C3F91D4 Q28388335-CD5160B1-DD7F-4ADA-8B51-457FFD55862C Q30615373-B2999C44-7E7E-43E6-AD67-B89310924599 Q33757232-C3FC9E62-4BDD-4F8A-AC24-E438EBA999EC Q34019744-AC5F1325-42A3-4F38-A44C-5622F8109EB0 Q35568191-74543F14-0D15-4E7C-9E16-4DB5B7C1CAE1 Q35698528-3CF97930-0CAB-4AFA-9ADA-F4D1052A4959 Q35816061-45C88F1C-7A25-4C79-8988-2A27C3CD02CA Q35919222-66501D78-22AA-4B02-9848-239A3B4E1797 Q36211648-37A482A9-AC84-4577-9CF4-7F2610A0E421 Q36518462-0AC06DB1-725B-419B-ACA1-8C5F4B9B90DB Q36946007-EF625E40-085E-4DFD-AA10-98D9B8D39E11 Q37084711-5F19B9D4-FF19-4204-99EE-C8A40018E323 Q37095523-68FA245E-5B97-407A-8506-B0DF7954016B Q37329555-804AEEEF-82CD-489C-AF4C-C0389452846E Q37343763-A3DC44DC-070C-47FB-AC76-990FFF96B186 Q37423512-DF524B89-CE10-4B2B-B3C7-847A3436AB1C Q37599856-21494722-5D48-483A-878C-3919483797FC Q37650465-4E31040F-3BD9-4995-B575-A30BC5E244D1 Q37762810-2681B56D-2315-45D5-BDB9-A683C4ACA06C Q37810097-4935A997-B90E-4339-84FD-4AD1828C2EFC Q37884088-9521B4DC-1DE2-4CD9-A1B2-FA61A5D52FAA Q37969225-F2705207-18D0-4839-BAFD-9B4E50543F8D Q38055398-F2C44333-2BBB-4A85-AC87-96D6DA31DF9D Q38112400-F733B913-1577-4E17-AE61-D39F322A45B4 Q38226394-792EA474-078F-4106-9633-411F1EC41154 Q38298216-829D500A-F0A3-449C-86CE-F458C3CDCCC2 Q38874222-AB472020-DAA2-468D-AD9A-4F8754C2D5DD Q39269756-22E425BD-ACF6-4C34-8AFB-D4C002054010 Q39865051-862DA2E1-55C5-437E-A7A8-B3C9FA858783 Q40077717-7D0A4DC6-2F84-4708-B314-D04F8F36C8E1 Q40098290-D201330E-01CB-4D67-8DCC-CDC38330C6BB Q40762243-9F362C8F-2177-4199-BE3A-AD28D069700B Q41687355-88056202-3AC9-4E1D-A3DE-3F99A5AD51AE Q41973193-83FA0BF5-3221-44A9-91A7-474FD13D0C9A Q42117340-D2B26344-C614-439E-95BE-E0B54640FD95 Q42588949-2A86DF0C-066A-4361-B3A7-29F7C738CD2C Q43199274-991546BA-B765-4FB5-985D-8A54E0A03C66 Q43226746-AB1AFFE1-74A9-4E40-ADBD-31B7C18EBA6D Q43235333-EE1D58C9-521D-46FD-8DBA-F6D1B2902282

P2860

Development of tridentate iron chelators: from desferrithiocin to ICL670.

http://www.wikidata.org/entity/Q35100327

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@ast

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@en

type

label

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@ast

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@en

prefLabel

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@ast

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@en

P1433

Q35100327-55031D95-AEE9-4045-AD12-EE47593D9877

P1476

Q35100327-4F66A3A4-40F1-4562-B1F6-D4D4ECB98808

P2093

Q35100327-64B1F1E0-4975-4340-BC96-943266616C67

Q35100327-73780921-21BD-4B6C-B030-ADC3C3CCC8AC

Q35100327-B3530C1E-0E02-47B2-9772-845EB7411F83

Q35100327-C2467E0F-75E7-4843-B23F-B99D0DAF2F57

Q35100327-D3758CA3-79D3-4A47-A38A-6BDA7A9731D2

Q35100327-E27FAFD8-DCAC-474F-8FE3-82BFE13884B5

Q35100327-F60C6C83-8471-4C1B-837E-EDB1CF0AB30E

P304

Q35100327-0B778CF5-B4E9-446E-8466-516CDD1AA3D8

P31

Q35100327-6E1B0FA4-26F9-45D0-A093-4A01CB14FBFB

P356

Q35100327-CCD554BB-EFAE-46DC-944D-6DD4F5AE612B

P433

Q35100327-00FC8441-139A-4AEA-9D53-A03753CC506D

P478

Q35100327-C6BE9BEF-8ACC-4B86-A8A6-BC3DDAB35F5D

P577

Q35100327-501BB364-37B0-4A5F-A23C-8A9365962DE7

P698

Q35100327-7ECEA4E5-5DBF-4E48-ABB7-B7928F2EFB3A

P356

0929867033457610

P1433

Current Medicinal Chemistry

P1476

Development of tridentate iron chelators: from desferrithiocin to ICL670.

@en

P2093

Daniele Alberti

http://www.w3.org/2001/XMLSchema#string

Hanspeter Nick

http://www.w3.org/2001/XMLSchema#string

Joachim Schupp

http://www.w3.org/2001/XMLSchema#string

Peter Buehlmayer

http://www.w3.org/2001/XMLSchema#string

Pierre Acklin

http://www.w3.org/2001/XMLSchema#string

René Lattmann

http://www.w3.org/2001/XMLSchema#string

Suzanne Hauffe

http://www.w3.org/2001/XMLSchema#string

P304

1065-1076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/0929867033457610

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12678677

http://www.w3.org/2001/XMLSchema#string